Tryptamine Therapeutics (AU:TYP) has released an update.
Tryptamine Therapeutics has appointed the eminent Professor David Castle to their Scientific Advisory Board, bringing his extensive experience in psychiatry and special interest in psychedelic treatments for mental health to the Company’s clinical trial programs. Professor Castle’s impressive academic and clinical background, including his role as a lead clinician in psilocybin studies and his expertise in grant funding, promises to support Tryp’s strategic direction and innovation in psychotherapy. His addition is expected to benefit the Company’s development of IV-infused psilocin for various unmet medical needs.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.